You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Moodys
McKinsey
Harvard Business School
Johnson and Johnson

Last Updated: February 26, 2024

REYVOW Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Reyvow patents expire, and what generic alternatives are available?

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-three countries.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.

DrugPatentWatch® Generic Entry Outlook for Reyvow

Reyvow was eligible for patent challenges on January 31, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for REYVOW
International Patents:85
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 84
Patent Applications: 72
Drug Prices: Drug price information for REYVOW
What excipients (inactive ingredients) are in REYVOW?REYVOW excipients list
DailyMed Link:REYVOW at DailyMed
Drug patent expirations by year for REYVOW
Drug Prices for REYVOW

See drug prices for REYVOW

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REYVOW
Generic Entry Date for REYVOW*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for REYVOW

US Patents and Regulatory Information for REYVOW

REYVOW is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of REYVOW is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting REYVOW

Compositions and methods related to pyridinoylpiperidine 5-HT.sub.1F agonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE

Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE

Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE

FDA Regulatory Exclusivity protecting REYVOW

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REYVOW

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for REYVOW

When does loss-of-exclusivity occur for REYVOW?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 17373784
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2019010934
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 43772
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 19001426
Estimated Expiration: ⤷  Try a Trial

China

Patent: 0291079
Estimated Expiration: ⤷  Try a Trial

Patent: 5385893
Estimated Expiration: ⤷  Try a Trial

Patent: 5385894
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 19005290
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 190251
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0211557
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 24540
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Dominican Republic

Patent: 019000139
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 19040190
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 1991112
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 56820
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 6598
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 20500936
Estimated Expiration: ⤷  Try a Trial

Patent: 22000451
Estimated Expiration: ⤷  Try a Trial

Patent: 23123678
Estimated Expiration: ⤷  Try a Trial

Jordan

Patent: 0190129
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 6855
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 19006520
Estimated Expiration: ⤷  Try a Trial

Patent: 21014139
Estimated Expiration: ⤷  Try a Trial

Moldova, Republic of

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 920
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 2906
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 191134
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 019501252
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 415
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 51617
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1903449
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 190075130
Estimated Expiration: ⤷  Try a Trial

Patent: 210102497
Estimated Expiration: ⤷  Try a Trial

Patent: 230008257
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 89476
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 71290
Estimated Expiration: ⤷  Try a Trial

Patent: 1833097
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 19000174
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 4433
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REYVOW around the world.

Country Patent Number Title Estimated Expiration
Peru 20191134 COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F ⤷  Try a Trial
Poland 210019 ⤷  Try a Trial
Japan 2010159272 PYRIDINOYL-PIPERIDINE AS 5-HT1F AGONIST ⤷  Try a Trial
Costa Rica 7496 PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5- HT1F ⤷  Try a Trial
Serbia 62415 FARMACEUTSKI OBLICI I METODE KOJI SE ODNOSE NA PIRIDINOILPIPERIDIN 5-HT1F AGONISTE (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) ⤷  Try a Trial
Peru 20030976 PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5-HT1F ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Moodys
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.